| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918911 | Radiotherapy and Oncology | 2013 | 5 Pages |
Abstract
Nelfinavir 750Â mg BID was defined as the recommended phase II dose in combination with capecitabine and 50.4Â Gy pre-operative radiotherapy in rectal cancer. First tumor response evaluations are promising, but a further phase II study is needed to get more information about efficacy of this treatment regimen.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jeroen Buijsen, Guido Lammering, Rob L.H. Jansen, Geerard L. Beets, Jaap Wals, Meindert Sosef, Marien O. Den Boer, Jeroen Leijtens, Robert G. Riedl, Jan Theys, Philippe Lambin,